Vivek K. Vishnudas MS, MBA, PhD

Vivek Vishnudas, Ph.D., oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies. Drug-discovery programs are based on the novel disease targets identified through the use of Interrogative Biology. Dr. Vishnudas leads an interdisciplinary team of drug-discovery scientists, biochemists and DMPK scientists to illuminate target biology & pharmacology while working closely with regulatory, analytics and biomarker teams.

Dr. Vishnudas manages the external R&D collaboration with industrial and academic partners, and aims to scale up Berg’s R&D therapeutics portfolio. He is a co-inventor of the Interrogative Biology technology, and continues to spearhead development activities of “data-driven” technologies that enable drug discovery programs. His breadth of operations covers scientific leadership, strategic R&D initiatives and commercial and intellectual property strategies.